Neuromyelitis optica (NMO), aka Devic disease, is one of those “looks-like-MS-until-it-doesn’t” conditions that shows up on Step questions as a trap. The giveaway is where the immune system attacks (optic nerves + spinal cord) and what it targets (aquaporin-4), which leads to different imaging, labs, and treatment than classic multiple sclerosis.
Where NMO Fits (and Why Step Cares)
NMO is an autoimmune demyelinating disease of the CNS characterized by:
- Optic neuritis (often severe, can be bilateral)
- Longitudinally extensive transverse myelitis (LETM): spinal cord inflammation spanning vertebral segments
- A key autoantibody: IgG against aquaporin-4 (AQP4) on astrocytic foot processes
On exams, NMO is high-yield because it:
- Mimics MS clinically
- Has distinct biomarkers, MRI patterns, and treatment
- Is worse with many MS disease-modifying therapies (important management pitfall)
Definition (Step-Ready)
Neuromyelitis optica (Devic disease) is an autoimmune inflammatory disorder of the CNS driven by AQP4-IgG (most common) leading to astrocyte injury, secondary demyelination, and classically optic neuritis + transverse myelitis.
First Aid cross-reference: Look under “Demyelinating diseases” (typically in the Neurology chapter near MS, optic neuritis, and transverse myelitis). NMO is commonly listed as an MS mimic with anti–AQP4.
Pathophysiology: The Core Mechanism You Need
The Key Target: Aquaporin-4
- Aquaporin-4 is a water channel heavily expressed on astrocyte end-feet at the blood–brain barrier.
- NMO is often AQP4-IgG positive (IgG1 subclass).
What the antibody does
AQP4-IgG binding triggers:
- Complement activation (think “more necrosis/severity than MS”)
- Neutrophil/eosinophil recruitment
- Astrocyte injury → secondary oligodendrocyte dysfunction → demyelination
Contrast with MS (high-yield distinction)
- NMO: primary astrocytopathy (AQP4), complement-mediated injury
- MS: primarily T-cell–mediated demyelination with oligoclonal bands and distinct periventricular plaques
Clinical Presentation: The Classic Pattern + The Sneaky Clues
Core attacks
-
Optic neuritis
- Pain with eye movement
- Decreased visual acuity, color desaturation
- Often more severe than MS; may be bilateral
-
Transverse myelitis (LETM)
- Acute/subacute weakness
- Sensory level
- Bowel/bladder dysfunction
- Back pain may occur
- MRI: lesion spanning vertebral segments (very Step-friendly)
Other high-yield NMO spectrum features
These are commonly tested as “extra” clues pointing away from MS:
- Area postrema syndrome: intractable hiccups and vomiting
- Brainstem symptoms
- Diencephalic/hypothalamic involvement (less common)
Demographics/associations (testable)
- More common in women
- Often associated with other autoimmune diseases (e.g., Sjögren, SLE)
Diagnosis: What Confirms NMO?
The most important test
- Serum AQP4-IgG positive strongly supports diagnosis
If AQP4-IgG is negative but the phenotype fits, consider MOG antibody-associated disease (MOGAD)—a related demyelinating syndrome with different relapse patterns and often better recovery.
MRI findings (very high yield)
Spinal cord MRI
- Longitudinally extensive lesion spanning vertebral segments
- Often central cord involvement
Brain MRI
- May be normal early (unlike MS)
- If abnormal, can involve areas rich in AQP4 (e.g., periependymal regions)
CSF clues (distinguish from MS)
- Oligoclonal bands: typically absent or less frequent than MS
- May show pleocytosis, sometimes with neutrophils (more inflammatory than classic MS)
Quick NMO vs MS Table (Exam-Favorite)
| Feature | Neuromyelitis Optica (NMO/Devic) | Multiple Sclerosis (MS) |
|---|---|---|
| Primary immune target | Aquaporin-4 on astrocytes | Myelin/oligodendrocytes (T-cell–mediated) |
| Key antibody | AQP4-IgG (often) | No single specific serum Ab |
| Core clinical pattern | Optic neuritis + LETM | Multifocal CNS deficits separated in time/space |
| Spinal cord MRI | vertebral segments | Usually shorter segments |
| Brain MRI | May be normal early | Periventricular plaques (e.g., Dawson fingers) |
| CSF oligoclonal bands | Less common | Common |
| Treatment approach | Immunosuppression; avoid many MS DMTs | MS disease-modifying therapies |
Treatment: Acute Attacks vs Relapse Prevention
Acute attack management (Step-style)
- High-dose IV glucocorticoids (e.g., methylprednisolone)
- If severe or steroid-refractory: plasmapheresis (PLEX)
Long-term relapse prevention
Goal: prevent future antibody-mediated attacks. Common strategies include:
- Rituximab (anti-CD20; B-cell depletion)
- Eculizumab (C5 inhibitor; blocks complement—mechanistically very “NMO-fitting”)
- Other immunosuppressants may be used depending on clinical context (e.g., azathioprine, mycophenolate)
High-yield warning: MS therapies can worsen NMO
Several MS disease-modifying therapies are not effective and may worsen NMO. On tests, if the stem strongly suggests NMO (AQP4-IgG+, LETM), the “start interferon beta” option should feel wrong.
High-Yield Associations & Classic Vignettes
“Classic” Step vignette
- Young/middle-aged woman with painful vision loss + acute paraplegia + urinary retention
- MRI spine: long segment lesion
- Serum: anti–AQP4 IgG
“Sneaky” vignette (area postrema)
- Persistent hiccups/vomiting + later optic neuritis/myelitis
- Think NMO spectrum disorder (AQP4-rich region involvement)
Autoimmune clustering
- NMO + Sjögren/SLE history is a common clue
First Aid-Style Memory Anchors
- NMO = “N” for “Neck (spinal cord) + Nerves (optic)”
- AQP4 is about water → think astrocyte end-feet at BBB
- Long spinal lesion ( levels) = NMO until proven otherwise
- Treat attacks with steroids/PLEX; prevent with immunosuppression (often B-cell/complement targeted)
Rapid-Fire USMLE Checklist (What to Recall in 10 Seconds)
- Dx: AQP4-IgG (serum), optic neuritis + LETM segments
- Path: antibody + complement → astrocyte injury
- CSF: OCBs usually negative/less common vs MS
- Acute tx: IV steroids → PLEX if refractory
- Prevention: rituximab, eculizumab, other immunosuppression
- Pitfall: don’t reflexively treat like MS